Physician profile
Christopher B Smith
NPI 1356780076
$1,428.20
in general payments reported to CMS, 2019-2025
14 companies · $86.41 in 2025
The $86.41 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $24.50 · 2021: $217 · 2022: $104 · 2023: $52.00 · 2024: $55.52 · 2025: $86.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $833.86 | 2019 | |
| Allergan, INC. | $130.61 | 2019-2021 | |
| Alcon Vision LLC | $118.14 | 2022-2025 | Clareon, Precision 7 |
| Glaukos Corporation | $61.77 | 2019-2023 | Kxl System (Not Refurbished) |
| Dompe US, INC. | $51.58 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.60 | 2019-2021 | |
| Vantage Technology LLC | $44.57 | 2025 | |
| Bausch & Lomb Americas INC. | $30.66 | 2022 | |
| Iridex Corporation | $24.50 | 2020 | |
| Amgen INC. | $22.70 | 2024 | Tepezza |
| Ivantis, INC | $17.18 | 2021 | |
| Biotissue Holdings INC. | $16.81 | 2024 | |
| Horizon Therapeutics Plc | $16.15 | 2021 | |
| Astellas Pharma US INC | $15.07 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.